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Myeloma accounts for thirteen percent of the haematological malignancies and 
two percent of all malignancies. According to Indian Cancer Registry Program’s 
consolidated report of population based cancer data (1990-96) the average age of 
Multiple myeloma diagnosis is 55 years. 
Conventionally, the investigations for diagnosis and remission status in MM is 
a cumbersome and painful procedure involving bone marrow studies, multiple blood 
investigations and skeletal survey with conventional radiography.  In this study we 
tried to compare the whole body PET CT scan to correlate disease burden in both 
multiple myeloma and plasmacytoma as measured by PET/CT scan with standard 
staging and prognostic parameters and also to evaluate response to induction therapy 
using PET based SUV changes. 
In our study we analysed the results of all myeloma patients who reported to 
our Institute from 1st Jan 2013 to 31st December 2014 and we had done PET scans for 
willing patients at the time of diagnosis and then at the end of planned induction 
therapy if they had achieved VGPR or better response. 
We had total of 31 patients who underwent PET CT scan as part of the study, 
Of these three patients  were upstaged to MM as they had multiple plasmacytomas and 
went on to receive treatment as MM. Of the treated cases of MM, 7 patients had 
VGPR or better response and they went ahead and got an end of treatment PET CT 
scan. The two patients who had stringent CR as per conventional criteria had no 
metabolic activity on the PET scan whereas  the other  two patients with CR response, 
one had absent metabolic activity while one had faint SUV of 1.2 and taken as CR. 
Of three cases with Plasmacytoma who underwent end of treatment PET CT 
scan, one had metabolic CR on PET while other two had small unicentric activity with 
SUV of 1 and 1.3 and they were kept under follow up. 
The overall survival and Event free survival at a median of 15 months in all the 
patients (n=112) was 76% and 43.1% respectively, following induction with novel 
agents. 
Although the numbers were very small and the follow up was limited, PET CT 
scan appears to be a promising investigation in diagnosis and staging MM as well as 
in establishing the remission status. Further continuation of the study and bigger 
patient population is required for more detailed analysis.  
 
